Protagonist Therapeutics Inc (PTGX)

Working capital turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Revenue (ttm) US$ in thousands 434,433 323,795 319,120 314,953 60,000 0 0 859 26,581 35,198 45,484 46,890 27,357 24,390 27,218 31,170 28,628 25,697 16,724 2,318
Total current assets US$ in thousands 591,641 476,769 570,925 627,553 355,577 324,881 316,941 235,736 237,355 276,617 304,302 341,522 340,736 327,687 371,818 285,508 315,606 204,151 217,466 125,986
Total current liabilities US$ in thousands 47,398 44,578 41,578 39,910 21,274 27,867 26,398 23,229 31,179 36,754 40,088 43,456 44,016 39,156 42,973 34,515 40,241 38,563 35,360 36,372
Working capital turnover 0.80 0.75 0.60 0.54 0.18 0.00 0.00 0.00 0.13 0.15 0.17 0.16 0.09 0.08 0.08 0.12 0.10 0.16 0.09 0.03

December 31, 2024 calculation

Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $434,433K ÷ ($591,641K – $47,398K)
= 0.80

The working capital turnover ratio displays how efficiently a company is utilizing its working capital to generate revenues. A higher turnover ratio indicates better efficiency in using the working capital to generate sales.

In the case of Protagonist Therapeutics Inc, the working capital turnover ratio has fluctuated over the analyzed periods. From March 31, 2020, to December 31, 2021, the ratio experienced some volatility, ranging from as low as 0.03 to as high as 0.16. This variability suggests inefficiencies in managing the working capital during this period.

However, starting from March 31, 2022, the working capital turnover ratio began to stabilize and show an improvement in efficiency. The ratio steadily increased to 0.80 by December 31, 2024, indicating that the company has been utilizing its working capital more effectively to drive sales and revenue growth.

Overall, the trend in the working capital turnover ratio for Protagonist Therapeutics Inc shows a transition from periods of inefficiency to enhanced efficiency in recent years, reflecting improved management of working capital resources and potentially better operational performance.